Home Cart Sign in  
Chemical Structure| 58749-22-7 Chemical Structure| 58749-22-7

Structure of Licochalcone A
CAS No.: 58749-22-7

Chemical Structure| 58749-22-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Licochalcone A, an estrogenic flavanoid, can be an inhibitor of p-glycoprotein and has anti-inflammatory actions.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Licochalcone A

CAS No. :58749-22-7
Formula : C21H22O4
M.W : 338.40
SMILES Code : O=C(C1=CC=C(O)C=C1)/C=C/C2=CC(C(C=C)(C)C)=C(O)C=C2OC
MDL No. :MFCD01417903
InChI Key :KAZSKMJFUPEHHW-DHZHZOJOSA-N
Pubchem ID :5318998

Safety of Licochalcone A

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H312-H332
Precautionary Statements:P280

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
SH-SY5Y cells 1 µM 7 days Promoted Nrf2 nuclear translocation and upregulated Nrf2 downstream gene expression, thereby protecting cells from oxidative stress damage PMC7433010
293 cells 1-10 µM 3 days Reduced Tau misfolding and associated ROS, promoted neurite outgrowth, and inhibited caspase 3 activity PMC7433010
ELT3 cells 0, 10, 20, 30, 40, 50, 60 µM 24 and 48 hours LicoA significantly inhibited ELT3 cell growth at concentrations above 20 µM, and the LDH cytotoxicity assay showed dose-dependent toxicity to ELT3 cells. PMC11851460
Uterine smooth muscle cells (UtSMCs) 0, 10, 20, 30, 40, 50, 60 µM 24 and 48 hours LicoA slightly inhibited UtSMCs growth at 50 and 60 µM after 24 hours, and significantly inhibited UtSMCs growth at concentrations above 30 µM after 48 hours. PMC11851460
Mouse mammary epithelial cells (mMECs) 1.2, 1.8, 2.4, 3 µg/mL 4 hours To evaluate the effect of Licochalcone A on cell viability, results showed that Licochalcone A inhibited LPS-induced inflammatory responses and increased the protein levels of ZO-1, occludin, and claudin3 PMC6398509
Mouse primary hepatocytes 10 μg/mL 24 hours To evaluate the effect of CVC on CCL2-induced hepatocyte steatosis. CVC down-regulated the fatty acid synthesis gene Fasn and up-regulated the fatty acid oxidation genes Acox-1, Pgc1α, and Ucp-2. PMC4416341
Normal osteoblast MC3T3-E1 cells 0, 20, 40, 60, 80, 100 μM 24 hours High concentration of LicA (60 μM) showed slight toxicity to MC3T3-E1 cells PMC6912226
Human osteosarcoma MG-63 cells 0, 20, 40, 60, 80, 100 μM 24 hours LicA significantly inhibited MG-63 cell proliferation in a dose-dependent manner PMC6912226
Human osteosarcoma 143B cells 0, 20, 40, 60, 80, 100 μM 24 hours LicA significantly inhibited 143B cell proliferation in a dose-dependent manner PMC6912226
Human osteosarcoma U2OS cells 0, 20, 40, 60, 80, 100 μM 24 hours LicA significantly inhibited U2OS cell proliferation in a dose-dependent manner PMC6912226
Human osteosarcoma HOS cells 0, 20, 40, 60, 80, 100 μM 24 hours LicA significantly inhibited HOS cell proliferation in a dose-dependent manner PMC6912226
BEAS-2B cells 0-20 μM 1 hour To evaluate the effects of Licochalcone A on oxidative responses and inflammatory cytokine levels. Licochalcone A significantly inhibited reactive oxygen species, eotaxin, and proinflammatory cytokines in BEAS-2B cells. PMC6628120
HepG2 hepatocytes 1.5–12 μM 24 hours To evaluate the effect of Licochalcone A on lipid metabolism, results showed that Licochalcone A significantly inhibited lipid droplet accumulation and lipoperoxidation PMC6562591
HepG2 cells 10 μg/mL 18 hours Evaluate the effect of SR9009 on BMAL1 mRNA expression PMC4416341

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
3×Tg-AD mice STZ-induced hyperglycemic model Intraperitoneal injection 40 mg/kg Once daily for 22 days Ameliorated spatial learning and memory deficits, reduced Aβ and Tau levels, and increased NRF2 and pCREB expression PMC7433010
BALB/c nude mice ELT3 tumor model Oral 10 and 20 mg/kg Twice a week for one month LicoA significantly suppressed ELT3 tumor growth and weight without affecting body weight, and no toxicity was observed. PMC11851460
C57BL/6 mice LPS/GalN-induced acute liver injury model Intraperitoneal injection 50 or 100 mg/kg Twice (12-hour interval) Lico A significantly reduced LPS/GalN-induced hepatotoxicity by lessening lethality, alleviating histopathological liver changes, decreasing ALT and AST levels, attenuating the secretion of inflammatory cytokines, and regulating oxidative markers. PMC6450927
C57BL6/J male mice LPS-induced neuroinflammation model Intraperitoneal injection 15 mg/kg/day 3 times per week for 2 weeks LCA protected against LPS alterations through its anti-inflammatory effect, reducing gliosis and regulating M1/M2 markers. PMC11812219
BALB/c mice LPS-induced mastitis model Injection 5, 10, 15 mg/kg Administered again 12 hours after LPS injection, lasting for 24 hours To evaluate the protective effect of Licochalcone A on mastitis, results showed that Licochalcone A significantly reduced pathological damage and inflammatory response, and improved the integrity of the blood-milk barrier PMC6398509
BALB/c nude mice 143B xenograft model Oral 10 mg/kg Twice a week for 5 weeks LicA significantly inhibited the growth of 143B xenograft tumors PMC6912226
BALB/c mice OVA-sensitized asthmatic mouse model Intraperitoneal injection 5 or 10 mg/kg Administered 1 hour before OVA challenge, continued until the end of the experiment To evaluate the effects of Licochalcone A on oxidative stress and airway inflammation in asthmatic mice. Licochalcone A significantly decreased oxidative responses, reduced malondialdehyde levels, and increased glutathione levels in the lungs, and decreased airway hyper-responsiveness, eosinophil infiltration, and Th2 cytokine production in the BALF. PMC6628120
C57BL/6 mice High-fat diet-induced obesity and NAFLD model Intraperitoneal injection 5 mg/kg and 10 mg/kg Twice a week for 12 weeks To investigate the ameliorative effects of Licochalcone A on obesity and NAFLD, results showed that Licochalcone A significantly reduced body weight, adipose tissue weight, and hepatic lipid accumulation PMC6562591

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.96mL

0.59mL

0.30mL

14.78mL

2.96mL

1.48mL

29.55mL

5.91mL

2.96mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories